CD4 and malaria: GLA-SE was selected based on its well-documented safety profile and its ability to enhance Th1-polarized CD4+ T-cell responses to co-administered antigens, particularly relevant as CD4+ T cells play a critical role in protective immunity against blood-stage malaria.